Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Akers Biosciences (AKER) Share Price

Media headlines about Akers Biosciences (NASDAQ:AKER) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akers Biosciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.6779159518752 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Akers Biosciences (NASDAQ AKER) traded down $0.13 on Wednesday, reaching $0.47. The company’s stock had a trading volume of 578,900 shares, compared to its average volume of 180,300. Akers Biosciences has a 52-week low of $0.36 and a 52-week high of $2.90.

Akers Biosciences (NASDAQ:AKER) last released its earnings results on Wednesday, November 15th. The medical instruments supplier reported ($0.13) earnings per share for the quarter. The firm had revenue of $0.68 million for the quarter. Akers Biosciences had a negative return on equity of 94.44% and a negative net margin of 134.31%.

Separately, ValuEngine upgraded Akers Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, December 1st.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Akers Biosciences (AKER) Share Price” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at

About Akers Biosciences

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Insider Buying and Selling by Quarter for Akers Biosciences (NASDAQ:AKER)

Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply